nodes	percent_of_prediction	percent_of_DWPC	metapath
Vandetanib—FLT4—polycystic ovary syndrome	0.339	0.477	CbGaD
Vandetanib—LTK—polycystic ovary syndrome	0.281	0.395	CbGaD
Vandetanib—VEGFA—polycystic ovary syndrome	0.0905	0.127	CbGaD
Vandetanib—BMPR1B—ovarian follicle—polycystic ovary syndrome	0.0076	0.0692	CbGeAlD
Vandetanib—Viral diarrhoea—Metformin—polycystic ovary syndrome	0.00313	0.145	CcSEcCtD
Vandetanib—Erlotinib—LTK—polycystic ovary syndrome	0.00291	0.798	CrCbGaD
Vandetanib—FMO3—urine—polycystic ovary syndrome	0.00214	0.0195	CbGeAlD
Vandetanib—Nail disorder—Metformin—polycystic ovary syndrome	0.00126	0.0583	CcSEcCtD
Vandetanib—Fungal infection—Metformin—polycystic ovary syndrome	0.00106	0.049	CcSEcCtD
Vandetanib—BLK—adrenal gland—polycystic ovary syndrome	0.000847	0.0077	CbGeAlD
Vandetanib—FLT4—embryo—polycystic ovary syndrome	0.000811	0.00737	CbGeAlD
Vandetanib—ERBB3—embryo—polycystic ovary syndrome	0.000772	0.00702	CbGeAlD
Vandetanib—PTK6—female gonad—polycystic ovary syndrome	0.000748	0.00681	CbGeAlD
Vandetanib—PTK6—vagina—polycystic ovary syndrome	0.000744	0.00677	CbGeAlD
Vandetanib—RET—embryo—polycystic ovary syndrome	0.000716	0.00651	CbGeAlD
Vandetanib—FGR—embryo—polycystic ovary syndrome	0.000716	0.00651	CbGeAlD
Vandetanib—PTK6—endocrine gland—polycystic ovary syndrome	0.000696	0.00633	CbGeAlD
Vandetanib—EPHA5—pituitary gland—polycystic ovary syndrome	0.000695	0.00632	CbGeAlD
Vandetanib—BMPR1B—uterus—polycystic ovary syndrome	0.000693	0.00631	CbGeAlD
Vandetanib—BMPR1B—adipose tissue—polycystic ovary syndrome	0.000678	0.00617	CbGeAlD
Vandetanib—FYN—embryo—polycystic ovary syndrome	0.000667	0.00607	CbGeAlD
Vandetanib—FLT4—adrenal cortex—polycystic ovary syndrome	0.000664	0.00604	CbGeAlD
Vandetanib—PLK4—adrenal gland—polycystic ovary syndrome	0.000661	0.00601	CbGeAlD
Vandetanib—VEGFA—adrenal cortex—polycystic ovary syndrome	0.000659	0.00599	CbGeAlD
Vandetanib—TEK—embryo—polycystic ovary syndrome	0.000652	0.00593	CbGeAlD
Vandetanib—IRAK4—adrenal cortex—polycystic ovary syndrome	0.000645	0.00587	CbGeAlD
Vandetanib—BMPR1B—adrenal gland—polycystic ovary syndrome	0.000608	0.00553	CbGeAlD
Vandetanib—Hypoglycaemia—Metformin—polycystic ovary syndrome	0.000607	0.0281	CcSEcCtD
Vandetanib—Lethargy—Metformin—polycystic ovary syndrome	0.000605	0.028	CcSEcCtD
Vandetanib—MKNK1—adrenal cortex—polycystic ovary syndrome	0.000594	0.0054	CbGeAlD
Vandetanib—RIPK2—endometrium—polycystic ovary syndrome	0.00059	0.00537	CbGeAlD
Vandetanib—VEGFA—endometrium—polycystic ovary syndrome	0.000588	0.00535	CbGeAlD
Vandetanib—FMO1—endometrium—polycystic ovary syndrome	0.000585	0.00532	CbGeAlD
Vandetanib—AXL—adrenal cortex—polycystic ovary syndrome	0.000584	0.00531	CbGeAlD
Vandetanib—EPHA6—endocrine gland—polycystic ovary syndrome	0.00058	0.00528	CbGeAlD
Vandetanib—SRC—embryo—polycystic ovary syndrome	0.000579	0.00527	CbGeAlD
Vandetanib—TYRO3—female gonad—polycystic ovary syndrome	0.000579	0.00527	CbGeAlD
Vandetanib—STK35—adipose tissue—polycystic ovary syndrome	0.000577	0.00525	CbGeAlD
Vandetanib—IRAK4—endometrium—polycystic ovary syndrome	0.000576	0.00524	CbGeAlD
Vandetanib—EPHA5—vagina—polycystic ovary syndrome	0.000575	0.00523	CbGeAlD
Vandetanib—PLK4—endocrine gland—polycystic ovary syndrome	0.000573	0.00521	CbGeAlD
Vandetanib—BMPR1B—female gonad—polycystic ovary syndrome	0.000567	0.00516	CbGeAlD
Vandetanib—FMO3—adrenal cortex—polycystic ovary syndrome	0.000566	0.00515	CbGeAlD
Vandetanib—ABL2—pituitary gland—polycystic ovary syndrome	0.000564	0.00513	CbGeAlD
Vandetanib—SLK—adrenal cortex—polycystic ovary syndrome	0.000562	0.00511	CbGeAlD
Vandetanib—ABL2—adipose tissue—polycystic ovary syndrome	0.000562	0.00511	CbGeAlD
Vandetanib—EGFR—uterus—polycystic ovary syndrome	0.000561	0.0051	CbGeAlD
Vandetanib—CYP3A4—urine—polycystic ovary syndrome	0.000559	0.00508	CbGeAlD
Vandetanib—Dehydration—Metformin—polycystic ovary syndrome	0.000551	0.0255	CcSEcCtD
Vandetanib—EGFR—adipose tissue—polycystic ovary syndrome	0.000548	0.00499	CbGeAlD
Vandetanib—VEGFA—uterus—polycystic ovary syndrome	0.000542	0.00493	CbGeAlD
Vandetanib—TYRO3—endocrine gland—polycystic ovary syndrome	0.000538	0.0049	CbGeAlD
Vandetanib—EPHA5—endocrine gland—polycystic ovary syndrome	0.000538	0.0049	CbGeAlD
Vandetanib—LYN—endocrine gland—polycystic ovary syndrome	0.000536	0.00487	CbGeAlD
Vandetanib—FLT4—adipose tissue—polycystic ovary syndrome	0.000535	0.00486	CbGeAlD
Vandetanib—TEK—adrenal cortex—polycystic ovary syndrome	0.000534	0.00486	CbGeAlD
Vandetanib—RIPK2—pituitary gland—polycystic ovary syndrome	0.000534	0.00486	CbGeAlD
Vandetanib—KDR—embryo—polycystic ovary syndrome	0.000533	0.00485	CbGeAlD
Vandetanib—VEGFA—pituitary gland—polycystic ovary syndrome	0.000532	0.00484	CbGeAlD
Vandetanib—RIPK2—adipose tissue—polycystic ovary syndrome	0.000532	0.00484	CbGeAlD
Vandetanib—VEGFA—adipose tissue—polycystic ovary syndrome	0.00053	0.00482	CbGeAlD
Vandetanib—MKNK1—endometrium—polycystic ovary syndrome	0.00053	0.00482	CbGeAlD
Vandetanib—Nasopharyngitis—Metformin—polycystic ovary syndrome	0.00053	0.0245	CcSEcCtD
Vandetanib—FMO1—pituitary gland—polycystic ovary syndrome	0.00053	0.00482	CbGeAlD
Vandetanib—FLT3—adrenal gland—polycystic ovary syndrome	0.000528	0.0048	CbGeAlD
Vandetanib—BMPR1B—endocrine gland—polycystic ovary syndrome	0.000528	0.0048	CbGeAlD
Vandetanib—FMO1—adipose tissue—polycystic ovary syndrome	0.000527	0.0048	CbGeAlD
Vandetanib—FGR—endometrium—polycystic ovary syndrome	0.000524	0.00476	CbGeAlD
Vandetanib—AXL—endometrium—polycystic ovary syndrome	0.000522	0.00474	CbGeAlD
Vandetanib—IRAK4—pituitary gland—polycystic ovary syndrome	0.000521	0.00474	CbGeAlD
Vandetanib—ERBB3—uterus—polycystic ovary syndrome	0.00052	0.00473	CbGeAlD
Vandetanib—IRAK4—adipose tissue—polycystic ovary syndrome	0.000519	0.00472	CbGeAlD
Vandetanib—STK35—adrenal gland—polycystic ovary syndrome	0.000517	0.00471	CbGeAlD
Vandetanib—Influenza—Metformin—polycystic ovary syndrome	0.000512	0.0237	CcSEcCtD
Vandetanib—ERBB3—adipose tissue—polycystic ovary syndrome	0.000509	0.00463	CbGeAlD
Vandetanib—ABL2—adrenal gland—polycystic ovary syndrome	0.000504	0.00459	CbGeAlD
Vandetanib—Pancreatitis—Metformin—polycystic ovary syndrome	0.000502	0.0233	CcSEcCtD
Vandetanib—SLK—endometrium—polycystic ovary syndrome	0.000502	0.00457	CbGeAlD
Vandetanib—YES1—adrenal cortex—polycystic ovary syndrome	0.000493	0.00449	CbGeAlD
Vandetanib—FLT3—female gonad—polycystic ovary syndrome	0.000492	0.00448	CbGeAlD
Vandetanib—EGFR—adrenal gland—polycystic ovary syndrome	0.000492	0.00448	CbGeAlD
Vandetanib—FYN—endometrium—polycystic ovary syndrome	0.000488	0.00444	CbGeAlD
Vandetanib—LCK—uterus—polycystic ovary syndrome	0.000483	0.00439	CbGeAlD
Vandetanib—STK35—female gonad—polycystic ovary syndrome	0.000482	0.00439	CbGeAlD
Vandetanib—AXL—uterus—polycystic ovary syndrome	0.000481	0.00437	CbGeAlD
Vandetanib—MKNK1—pituitary gland—polycystic ovary syndrome	0.00048	0.00436	CbGeAlD
Vandetanib—FLT4—adrenal gland—polycystic ovary syndrome	0.00048	0.00436	CbGeAlD
Vandetanib—STK35—vagina—polycystic ovary syndrome	0.000479	0.00436	CbGeAlD
Vandetanib—Neutropenia—Metformin—polycystic ovary syndrome	0.000479	0.0222	CcSEcCtD
Vandetanib—MKNK1—adipose tissue—polycystic ovary syndrome	0.000478	0.00435	CbGeAlD
Vandetanib—MAP4K5—endometrium—polycystic ovary syndrome	0.000477	0.00434	CbGeAlD
Vandetanib—TEK—endometrium—polycystic ovary syndrome	0.000477	0.00434	CbGeAlD
Vandetanib—RIPK2—adrenal gland—polycystic ovary syndrome	0.000477	0.00434	CbGeAlD
Vandetanib—Upper respiratory tract infection—Metformin—polycystic ovary syndrome	0.000476	0.0221	CcSEcCtD
Vandetanib—VEGFA—adrenal gland—polycystic ovary syndrome	0.000476	0.00433	CbGeAlD
Vandetanib—FGR—pituitary gland—polycystic ovary syndrome	0.000474	0.00431	CbGeAlD
Vandetanib—RET—pituitary gland—polycystic ovary syndrome	0.000474	0.00431	CbGeAlD
Vandetanib—FMO1—adrenal gland—polycystic ovary syndrome	0.000473	0.0043	CbGeAlD
Vandetanib—AXL—pituitary gland—polycystic ovary syndrome	0.000472	0.00429	CbGeAlD
Vandetanib—FGR—adipose tissue—polycystic ovary syndrome	0.000472	0.00429	CbGeAlD
Vandetanib—LCK—adipose tissue—polycystic ovary syndrome	0.000472	0.00429	CbGeAlD
Vandetanib—AXL—adipose tissue—polycystic ovary syndrome	0.00047	0.00428	CbGeAlD
Vandetanib—ABL2—female gonad—polycystic ovary syndrome	0.00047	0.00428	CbGeAlD
Vandetanib—ABL2—vagina—polycystic ovary syndrome	0.000467	0.00425	CbGeAlD
Vandetanib—IRAK4—adrenal gland—polycystic ovary syndrome	0.000466	0.00424	CbGeAlD
Vandetanib—SLK—uterus—polycystic ovary syndrome	0.000463	0.00421	CbGeAlD
Vandetanib—PDGFRB—embryo—polycystic ovary syndrome	0.000461	0.0042	CbGeAlD
Vandetanib—EGFR—female gonad—polycystic ovary syndrome	0.000459	0.00417	CbGeAlD
Vandetanib—FLT3—endocrine gland—polycystic ovary syndrome	0.000458	0.00416	CbGeAlD
Vandetanib—FMO3—pituitary gland—polycystic ovary syndrome	0.000458	0.00416	CbGeAlD
Vandetanib—Infestation—Metformin—polycystic ovary syndrome	0.000457	0.0212	CcSEcCtD
Vandetanib—Infestation NOS—Metformin—polycystic ovary syndrome	0.000457	0.0212	CcSEcCtD
Vandetanib—EPHB6—endometrium—polycystic ovary syndrome	0.000456	0.00415	CbGeAlD
Vandetanib—FMO3—adipose tissue—polycystic ovary syndrome	0.000456	0.00415	CbGeAlD
Vandetanib—SLK—pituitary gland—polycystic ovary syndrome	0.000454	0.00413	CbGeAlD
Vandetanib—SLK—adipose tissue—polycystic ovary syndrome	0.000452	0.00412	CbGeAlD
Vandetanib—Erlotinib—CYP1A1—polycystic ovary syndrome	0.000452	0.124	CrCbGaD
Vandetanib—FYN—uterus—polycystic ovary syndrome	0.00045	0.00409	CbGeAlD
Vandetanib—STK35—endocrine gland—polycystic ovary syndrome	0.000449	0.00408	CbGeAlD
Vandetanib—FLT4—female gonad—polycystic ovary syndrome	0.000447	0.00407	CbGeAlD
Vandetanib—RIPK2—female gonad—polycystic ovary syndrome	0.000445	0.00405	CbGeAlD
Vandetanib—VEGFA—female gonad—polycystic ovary syndrome	0.000443	0.00403	CbGeAlD
Vandetanib—RIPK2—vagina—polycystic ovary syndrome	0.000442	0.00402	CbGeAlD
Vandetanib—FYN—pituitary gland—polycystic ovary syndrome	0.000442	0.00402	CbGeAlD
Vandetanib—FMO1—female gonad—polycystic ovary syndrome	0.000441	0.00401	CbGeAlD
Vandetanib—VEGFA—vagina—polycystic ovary syndrome	0.000441	0.00401	CbGeAlD
Vandetanib—YES1—endometrium—polycystic ovary syndrome	0.000441	0.00401	CbGeAlD
Vandetanib—FYN—adipose tissue—polycystic ovary syndrome	0.00044	0.004	CbGeAlD
Vandetanib—MAP4K5—uterus—polycystic ovary syndrome	0.00044	0.004	CbGeAlD
Vandetanib—TEK—uterus—polycystic ovary syndrome	0.00044	0.004	CbGeAlD
Vandetanib—FMO1—vagina—polycystic ovary syndrome	0.000438	0.00399	CbGeAlD
Vandetanib—KDR—adrenal cortex—polycystic ovary syndrome	0.000437	0.00397	CbGeAlD
Vandetanib—MAP2K5—adrenal cortex—polycystic ovary syndrome	0.000437	0.00397	CbGeAlD
Vandetanib—IRAK4—female gonad—polycystic ovary syndrome	0.000434	0.00395	CbGeAlD
Vandetanib—Hepatobiliary disease—Metformin—polycystic ovary syndrome	0.000432	0.02	CcSEcCtD
Vandetanib—MAP4K5—pituitary gland—polycystic ovary syndrome	0.000432	0.00393	CbGeAlD
Vandetanib—TEK—pituitary gland—polycystic ovary syndrome	0.000432	0.00393	CbGeAlD
Vandetanib—IRAK4—vagina—polycystic ovary syndrome	0.000432	0.00393	CbGeAlD
Vandetanib—MAP4K5—adipose tissue—polycystic ovary syndrome	0.00043	0.00391	CbGeAlD
Vandetanib—TEK—adipose tissue—polycystic ovary syndrome	0.00043	0.00391	CbGeAlD
Vandetanib—MKNK1—adrenal gland—polycystic ovary syndrome	0.000429	0.0039	CbGeAlD
Vandetanib—ERBB3—female gonad—polycystic ovary syndrome	0.000426	0.00387	CbGeAlD
Vandetanib—FGR—adrenal gland—polycystic ovary syndrome	0.000423	0.00385	CbGeAlD
Vandetanib—RET—adrenal gland—polycystic ovary syndrome	0.000423	0.00385	CbGeAlD
Vandetanib—LCK—adrenal gland—polycystic ovary syndrome	0.000423	0.00385	CbGeAlD
Vandetanib—AXL—adrenal gland—polycystic ovary syndrome	0.000422	0.00384	CbGeAlD
Vandetanib—Bradycardia—Metformin—polycystic ovary syndrome	0.000417	0.0193	CcSEcCtD
Vandetanib—FLT4—endocrine gland—polycystic ovary syndrome	0.000416	0.00378	CbGeAlD
Vandetanib—RIPK2—endocrine gland—polycystic ovary syndrome	0.000414	0.00376	CbGeAlD
Vandetanib—EPHB6—pituitary gland—polycystic ovary syndrome	0.000413	0.00375	CbGeAlD
Vandetanib—ABL1—embryo—polycystic ovary syndrome	0.000411	0.00374	CbGeAlD
Vandetanib—EPHB6—adipose tissue—polycystic ovary syndrome	0.000411	0.00374	CbGeAlD
Vandetanib—FMO1—endocrine gland—polycystic ovary syndrome	0.00041	0.00373	CbGeAlD
Vandetanib—FMO3—adrenal gland—polycystic ovary syndrome	0.000409	0.00372	CbGeAlD
Vandetanib—YES1—uterus—polycystic ovary syndrome	0.000406	0.00369	CbGeAlD
Vandetanib—SLK—adrenal gland—polycystic ovary syndrome	0.000406	0.00369	CbGeAlD
Vandetanib—STK10—uterus—polycystic ovary syndrome	0.000402	0.00366	CbGeAlD
Vandetanib—MKNK1—female gonad—polycystic ovary syndrome	0.0004	0.00364	CbGeAlD
Vandetanib—YES1—pituitary gland—polycystic ovary syndrome	0.000399	0.00363	CbGeAlD
Vandetanib—MKNK1—vagina—polycystic ovary syndrome	0.000397	0.00361	CbGeAlD
Vandetanib—YES1—adipose tissue—polycystic ovary syndrome	0.000397	0.00361	CbGeAlD
Vandetanib—ERBB3—endocrine gland—polycystic ovary syndrome	0.000396	0.0036	CbGeAlD
Vandetanib—FGR—female gonad—polycystic ovary syndrome	0.000395	0.00359	CbGeAlD
Vandetanib—LCK—female gonad—polycystic ovary syndrome	0.000395	0.00359	CbGeAlD
Vandetanib—FYN—adrenal gland—polycystic ovary syndrome	0.000395	0.00359	CbGeAlD
Vandetanib—STK10—adipose tissue—polycystic ovary syndrome	0.000393	0.00358	CbGeAlD
Vandetanib—AXL—female gonad—polycystic ovary syndrome	0.000393	0.00358	CbGeAlD
Vandetanib—FGR—vagina—polycystic ovary syndrome	0.000392	0.00357	CbGeAlD
Vandetanib—LCK—vagina—polycystic ovary syndrome	0.000392	0.00357	CbGeAlD
Vandetanib—AXL—vagina—polycystic ovary syndrome	0.000391	0.00355	CbGeAlD
Vandetanib—MAP2K5—endometrium—polycystic ovary syndrome	0.00039	0.00355	CbGeAlD
Vandetanib—KDR—endometrium—polycystic ovary syndrome	0.00039	0.00355	CbGeAlD
Vandetanib—TEK—adrenal gland—polycystic ovary syndrome	0.000386	0.00351	CbGeAlD
Vandetanib—MAP4K5—adrenal gland—polycystic ovary syndrome	0.000386	0.00351	CbGeAlD
Vandetanib—Eye disorder—Metformin—polycystic ovary syndrome	0.000383	0.0177	CcSEcCtD
Vandetanib—SRC—adipose tissue—polycystic ovary syndrome	0.000382	0.00347	CbGeAlD
Vandetanib—Cardiac disorder—Metformin—polycystic ovary syndrome	0.00038	0.0176	CcSEcCtD
Vandetanib—FMO3—vagina—polycystic ovary syndrome	0.000379	0.00345	CbGeAlD
Vandetanib—SLK—female gonad—polycystic ovary syndrome	0.000378	0.00344	CbGeAlD
Vandetanib—PDGFRB—adrenal cortex—polycystic ovary syndrome	0.000378	0.00344	CbGeAlD
Vandetanib—SLK—vagina—polycystic ovary syndrome	0.000376	0.00342	CbGeAlD
Vandetanib—Angiopathy—Metformin—polycystic ovary syndrome	0.000372	0.0172	CcSEcCtD
Vandetanib—MKNK1—endocrine gland—polycystic ovary syndrome	0.000372	0.00338	CbGeAlD
Vandetanib—Mediastinal disorder—Metformin—polycystic ovary syndrome	0.000369	0.0171	CcSEcCtD
Vandetanib—EPHB6—adrenal gland—polycystic ovary syndrome	0.000369	0.00335	CbGeAlD
Vandetanib—FYN—female gonad—polycystic ovary syndrome	0.000368	0.00335	CbGeAlD
Vandetanib—FGR—endocrine gland—polycystic ovary syndrome	0.000367	0.00334	CbGeAlD
Vandetanib—RET—endocrine gland—polycystic ovary syndrome	0.000367	0.00334	CbGeAlD
Vandetanib—FYN—vagina—polycystic ovary syndrome	0.000366	0.00333	CbGeAlD
Vandetanib—AXL—endocrine gland—polycystic ovary syndrome	0.000366	0.00333	CbGeAlD
Vandetanib—MAP4K5—female gonad—polycystic ovary syndrome	0.00036	0.00327	CbGeAlD
Vandetanib—TEK—female gonad—polycystic ovary syndrome	0.00036	0.00327	CbGeAlD
Vandetanib—KDR—uterus—polycystic ovary syndrome	0.000359	0.00327	CbGeAlD
Vandetanib—MAP4K5—vagina—polycystic ovary syndrome	0.000357	0.00325	CbGeAlD
Vandetanib—Malnutrition—Metformin—polycystic ovary syndrome	0.000357	0.0165	CcSEcCtD
Vandetanib—YES1—adrenal gland—polycystic ovary syndrome	0.000356	0.00324	CbGeAlD
Vandetanib—FMO3—endocrine gland—polycystic ovary syndrome	0.000355	0.00323	CbGeAlD
Vandetanib—STK10—adrenal gland—polycystic ovary syndrome	0.000353	0.00321	CbGeAlD
Vandetanib—KDR—pituitary gland—polycystic ovary syndrome	0.000353	0.00321	CbGeAlD
Vandetanib—MAP2K5—pituitary gland—polycystic ovary syndrome	0.000353	0.00321	CbGeAlD
Vandetanib—KDR—adipose tissue—polycystic ovary syndrome	0.000351	0.0032	CbGeAlD
Vandetanib—MAP2K5—adipose tissue—polycystic ovary syndrome	0.000351	0.0032	CbGeAlD
Vandetanib—Dysgeusia—Metformin—polycystic ovary syndrome	0.000349	0.0162	CcSEcCtD
Vandetanib—EPHB6—female gonad—polycystic ovary syndrome	0.000344	0.00313	CbGeAlD
Vandetanib—Muscle spasms—Metformin—polycystic ovary syndrome	0.000343	0.0159	CcSEcCtD
Vandetanib—SRC—adrenal gland—polycystic ovary syndrome	0.000343	0.00312	CbGeAlD
Vandetanib—FYN—endocrine gland—polycystic ovary syndrome	0.000342	0.00311	CbGeAlD
Vandetanib—EPHB6—vagina—polycystic ovary syndrome	0.000342	0.00311	CbGeAlD
Vandetanib—PDGFRB—endometrium—polycystic ovary syndrome	0.000337	0.00307	CbGeAlD
Vandetanib—ABL1—adrenal cortex—polycystic ovary syndrome	0.000337	0.00306	CbGeAlD
Vandetanib—Vision blurred—Metformin—polycystic ovary syndrome	0.000336	0.0156	CcSEcCtD
Vandetanib—TEK—endocrine gland—polycystic ovary syndrome	0.000334	0.00304	CbGeAlD
Vandetanib—MAP4K5—endocrine gland—polycystic ovary syndrome	0.000334	0.00304	CbGeAlD
Vandetanib—Tremor—Metformin—polycystic ovary syndrome	0.000334	0.0155	CcSEcCtD
Vandetanib—YES1—female gonad—polycystic ovary syndrome	0.000332	0.00302	CbGeAlD
Vandetanib—YES1—vagina—polycystic ovary syndrome	0.00033	0.003	CbGeAlD
Vandetanib—STK10—female gonad—polycystic ovary syndrome	0.000329	0.00299	CbGeAlD
Vandetanib—STK10—vagina—polycystic ovary syndrome	0.000327	0.00298	CbGeAlD
Vandetanib—SRC—female gonad—polycystic ovary syndrome	0.000319	0.00291	CbGeAlD
Vandetanib—ORM1—endometrium—polycystic ovary syndrome	0.000317	0.00288	CbGeAlD
Vandetanib—KDR—adrenal gland—polycystic ovary syndrome	0.000315	0.00287	CbGeAlD
Vandetanib—MAP2K5—adrenal gland—polycystic ovary syndrome	0.000315	0.00287	CbGeAlD
Vandetanib—Loss of consciousness—Metformin—polycystic ovary syndrome	0.000314	0.0145	CcSEcCtD
Vandetanib—PDGFRB—uterus—polycystic ovary syndrome	0.000311	0.00283	CbGeAlD
Vandetanib—YES1—endocrine gland—polycystic ovary syndrome	0.000309	0.00281	CbGeAlD
Vandetanib—Hypertension—Metformin—polycystic ovary syndrome	0.000308	0.0143	CcSEcCtD
Vandetanib—STK10—endocrine gland—polycystic ovary syndrome	0.000306	0.00278	CbGeAlD
Vandetanib—PDGFRB—pituitary gland—polycystic ovary syndrome	0.000305	0.00278	CbGeAlD
Vandetanib—PDGFRB—adipose tissue—polycystic ovary syndrome	0.000304	0.00277	CbGeAlD
Vandetanib—Chest pain—Metformin—polycystic ovary syndrome	0.000304	0.0141	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Metformin—polycystic ovary syndrome	0.000302	0.014	CcSEcCtD
Vandetanib—ABL1—endometrium—polycystic ovary syndrome	0.000301	0.00274	CbGeAlD
Vandetanib—SRC—endocrine gland—polycystic ovary syndrome	0.000297	0.0027	CbGeAlD
Vandetanib—KDR—female gonad—polycystic ovary syndrome	0.000294	0.00267	CbGeAlD
Vandetanib—MAP2K5—female gonad—polycystic ovary syndrome	0.000294	0.00267	CbGeAlD
Vandetanib—KDR—vagina—polycystic ovary syndrome	0.000292	0.00266	CbGeAlD
Vandetanib—MAP2K5—vagina—polycystic ovary syndrome	0.000292	0.00266	CbGeAlD
Vandetanib—Oedema—Metformin—polycystic ovary syndrome	0.000291	0.0135	CcSEcCtD
Vandetanib—Infection—Metformin—polycystic ovary syndrome	0.000289	0.0134	CcSEcCtD
Vandetanib—Nervous system disorder—Metformin—polycystic ovary syndrome	0.000286	0.0132	CcSEcCtD
Vandetanib—Thrombocytopenia—Metformin—polycystic ovary syndrome	0.000285	0.0132	CcSEcCtD
Vandetanib—Skin disorder—Metformin—polycystic ovary syndrome	0.000283	0.0131	CcSEcCtD
Vandetanib—Gefitinib—CYP1A1—polycystic ovary syndrome	0.000283	0.0777	CrCbGaD
Vandetanib—ABL1—uterus—polycystic ovary syndrome	0.000277	0.00252	CbGeAlD
Vandetanib—KDR—endocrine gland—polycystic ovary syndrome	0.000273	0.00249	CbGeAlD
Vandetanib—MAP2K5—endocrine gland—polycystic ovary syndrome	0.000273	0.00249	CbGeAlD
Vandetanib—PDGFRB—adrenal gland—polycystic ovary syndrome	0.000273	0.00248	CbGeAlD
Vandetanib—ABL1—pituitary gland—polycystic ovary syndrome	0.000272	0.00248	CbGeAlD
Vandetanib—ABL1—adipose tissue—polycystic ovary syndrome	0.000271	0.00247	CbGeAlD
Vandetanib—Musculoskeletal discomfort—Metformin—polycystic ovary syndrome	0.000265	0.0123	CcSEcCtD
Vandetanib—Paraesthesia—Metformin—polycystic ovary syndrome	0.000262	0.0121	CcSEcCtD
Vandetanib—Dyspnoea—Metformin—polycystic ovary syndrome	0.00026	0.012	CcSEcCtD
Vandetanib—ABCC1—adrenal cortex—polycystic ovary syndrome	0.000257	0.00233	CbGeAlD
Vandetanib—Dyspepsia—Metformin—polycystic ovary syndrome	0.000256	0.0119	CcSEcCtD
Vandetanib—PDGFRB—female gonad—polycystic ovary syndrome	0.000254	0.00231	CbGeAlD
Vandetanib—Decreased appetite—Metformin—polycystic ovary syndrome	0.000253	0.0117	CcSEcCtD
Vandetanib—PDGFRB—vagina—polycystic ovary syndrome	0.000253	0.0023	CbGeAlD
Vandetanib—Gastrointestinal disorder—Metformin—polycystic ovary syndrome	0.000251	0.0116	CcSEcCtD
Vandetanib—Fatigue—Metformin—polycystic ovary syndrome	0.000251	0.0116	CcSEcCtD
Vandetanib—Constipation—Metformin—polycystic ovary syndrome	0.000249	0.0115	CcSEcCtD
Vandetanib—ABL1—adrenal gland—polycystic ovary syndrome	0.000243	0.00221	CbGeAlD
Vandetanib—Gastrointestinal pain—Metformin—polycystic ovary syndrome	0.000238	0.011	CcSEcCtD
Vandetanib—PDGFRB—endocrine gland—polycystic ovary syndrome	0.000237	0.00215	CbGeAlD
Vandetanib—Abdominal pain—Metformin—polycystic ovary syndrome	0.00023	0.0107	CcSEcCtD
Vandetanib—ABCC1—endometrium—polycystic ovary syndrome	0.000229	0.00208	CbGeAlD
Vandetanib—ABL1—female gonad—polycystic ovary syndrome	0.000227	0.00206	CbGeAlD
Vandetanib—ABL1—vagina—polycystic ovary syndrome	0.000225	0.00205	CbGeAlD
Vandetanib—ALB—adrenal gland—polycystic ovary syndrome	0.000224	0.00204	CbGeAlD
Vandetanib—ORM1—endocrine gland—polycystic ovary syndrome	0.000222	0.00202	CbGeAlD
Vandetanib—ABCG2—adrenal cortex—polycystic ovary syndrome	0.000212	0.00193	CbGeAlD
Vandetanib—ABCC1—uterus—polycystic ovary syndrome	0.000211	0.00192	CbGeAlD
Vandetanib—ABL1—endocrine gland—polycystic ovary syndrome	0.000211	0.00192	CbGeAlD
Vandetanib—Asthenia—Metformin—polycystic ovary syndrome	0.000209	0.00968	CcSEcCtD
Vandetanib—ABCC1—pituitary gland—polycystic ovary syndrome	0.000207	0.00189	CbGeAlD
Vandetanib—ABCC1—adipose tissue—polycystic ovary syndrome	0.000206	0.00188	CbGeAlD
Vandetanib—Pruritus—Metformin—polycystic ovary syndrome	0.000206	0.00955	CcSEcCtD
Vandetanib—Diarrhoea—Metformin—polycystic ovary syndrome	0.000199	0.00923	CcSEcCtD
Vandetanib—Dizziness—Metformin—polycystic ovary syndrome	0.000193	0.00892	CcSEcCtD
Vandetanib—ABCG2—endometrium—polycystic ovary syndrome	0.00019	0.00173	CbGeAlD
Vandetanib—ABCC1—adrenal gland—polycystic ovary syndrome	0.000185	0.00168	CbGeAlD
Vandetanib—Vomiting—Metformin—polycystic ovary syndrome	0.000185	0.00858	CcSEcCtD
Vandetanib—Rash—Metformin—polycystic ovary syndrome	0.000184	0.00851	CcSEcCtD
Vandetanib—Dermatitis—Metformin—polycystic ovary syndrome	0.000183	0.0085	CcSEcCtD
Vandetanib—Headache—Metformin—polycystic ovary syndrome	0.000182	0.00845	CcSEcCtD
Vandetanib—ABCG2—uterus—polycystic ovary syndrome	0.000175	0.00159	CbGeAlD
Vandetanib—Nausea—Metformin—polycystic ovary syndrome	0.000173	0.00801	CcSEcCtD
Vandetanib—ABCC1—female gonad—polycystic ovary syndrome	0.000173	0.00157	CbGeAlD
Vandetanib—ABCC1—vagina—polycystic ovary syndrome	0.000172	0.00156	CbGeAlD
Vandetanib—ABCG2—pituitary gland—polycystic ovary syndrome	0.000172	0.00156	CbGeAlD
Vandetanib—ABCG2—adipose tissue—polycystic ovary syndrome	0.000171	0.00156	CbGeAlD
Vandetanib—ABCG2—adrenal gland—polycystic ovary syndrome	0.000153	0.00139	CbGeAlD
Vandetanib—ABCG2—female gonad—polycystic ovary syndrome	0.000143	0.0013	CbGeAlD
Vandetanib—ABCG2—vagina—polycystic ovary syndrome	0.000142	0.00129	CbGeAlD
Vandetanib—CYP3A4—endocrine gland—polycystic ovary syndrome	9.26e-05	0.000843	CbGeAlD
Vandetanib—PDGFRB—Signaling Pathways—NCOR1—polycystic ovary syndrome	3.24e-06	2.1e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—IRS2—polycystic ovary syndrome	3.24e-06	2.1e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—IRS1—polycystic ovary syndrome	3.23e-06	2.09e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—POMC—polycystic ovary syndrome	3.23e-06	2.09e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—NRG1—polycystic ovary syndrome	3.22e-06	2.09e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—PRL—polycystic ovary syndrome	3.22e-06	2.08e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—NRG1—polycystic ovary syndrome	3.18e-06	2.06e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—NCOR1—polycystic ovary syndrome	3.17e-06	2.05e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—SERPINE1—polycystic ovary syndrome	3.16e-06	2.05e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—GNAS—polycystic ovary syndrome	3.16e-06	2.05e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—PLAT—polycystic ovary syndrome	3.15e-06	2.04e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—GHRL—polycystic ovary syndrome	3.15e-06	2.04e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—AKT2—polycystic ovary syndrome	3.14e-06	2.03e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—INS—polycystic ovary syndrome	3.13e-06	2.03e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—YAP1—polycystic ovary syndrome	3.13e-06	2.03e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—NGFR—polycystic ovary syndrome	3.13e-06	2.03e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—SERPINE1—polycystic ovary syndrome	3.13e-06	2.03e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—NCOR1—polycystic ovary syndrome	3.12e-06	2.02e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—IRS1—polycystic ovary syndrome	3.12e-06	2.02e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—IRS2—polycystic ovary syndrome	3.12e-06	2.02e-05	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—IGF1—polycystic ovary syndrome	3.11e-06	2.02e-05	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—AKT2—polycystic ovary syndrome	3.11e-06	2.02e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—NRG1—polycystic ovary syndrome	3.11e-06	2.02e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—POMC—polycystic ovary syndrome	3.11e-06	2.02e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—AKT2—polycystic ovary syndrome	3.1e-06	2.01e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—PRL—polycystic ovary syndrome	3.1e-06	2.01e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—INS—polycystic ovary syndrome	3.09e-06	2e-05	CbGpPWpGaD
Vandetanib—SRC—Developmental Biology—VEGFA—polycystic ovary syndrome	3.07e-06	1.99e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—NRG1—polycystic ovary syndrome	3.06e-06	1.98e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—IRS1—polycystic ovary syndrome	3.06e-06	1.98e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—ADRB2—polycystic ovary syndrome	3.05e-06	1.98e-05	CbGpPWpGaD
Vandetanib—FLT4—Signaling Pathways—IL6—polycystic ovary syndrome	3.03e-06	1.96e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—AKT2—polycystic ovary syndrome	3.03e-06	1.96e-05	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—MTHFR—polycystic ovary syndrome	3.02e-06	1.96e-05	CbGpPWpGaD
Vandetanib—SRC—Hemostasis—VEGFA—polycystic ovary syndrome	3.01e-06	1.95e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—NCOR1—polycystic ovary syndrome	3.01e-06	1.95e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—NAMPT—polycystic ovary syndrome	3.01e-06	1.95e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—POMC—polycystic ovary syndrome	3.01e-06	1.95e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—ATF1—polycystic ovary syndrome	3e-06	1.94e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—IRS1—polycystic ovary syndrome	3e-06	1.94e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—IGF1—polycystic ovary syndrome	2.99e-06	1.94e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—IRS2—polycystic ovary syndrome	2.99e-06	1.94e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—CRP—polycystic ovary syndrome	2.99e-06	1.94e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—AKT2—polycystic ovary syndrome	2.99e-06	1.94e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism of lipids and lipoproteins—PPARG—polycystic ovary syndrome	2.99e-06	1.94e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—INS—polycystic ovary syndrome	2.99e-06	1.94e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—SERPINE1—polycystic ovary syndrome	2.99e-06	1.93e-05	CbGpPWpGaD
Vandetanib—SRC—Axon guidance—IL6—polycystic ovary syndrome	2.98e-06	1.93e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—BCL2—polycystic ovary syndrome	2.97e-06	1.93e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—CYP11A1—polycystic ovary syndrome	2.97e-06	1.92e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PNPLA2—polycystic ovary syndrome	2.96e-06	1.92e-05	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—SERPINE1—polycystic ovary syndrome	2.96e-06	1.92e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—IRS1—polycystic ovary syndrome	2.95e-06	1.91e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism of lipids and lipoproteins—POMC—polycystic ovary syndrome	2.95e-06	1.91e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—ADRB2—polycystic ovary syndrome	2.94e-06	1.91e-05	CbGpPWpGaD
Vandetanib—LYN—Developmental Biology—IL6—polycystic ovary syndrome	2.93e-06	1.9e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—TCF7L2—polycystic ovary syndrome	2.93e-06	1.9e-05	CbGpPWpGaD
Vandetanib—ABL1—Developmental Biology—IL6—polycystic ovary syndrome	2.91e-06	1.89e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—BCL2—polycystic ovary syndrome	2.91e-06	1.88e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—MTHFR—polycystic ovary syndrome	2.9e-06	1.88e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—BCL2—polycystic ovary syndrome	2.9e-06	1.88e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—IGF1—polycystic ovary syndrome	2.89e-06	1.87e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—AKT2—polycystic ovary syndrome	2.89e-06	1.87e-05	CbGpPWpGaD
Vandetanib—IRAK4—Immune System—IL6—polycystic ovary syndrome	2.89e-06	1.87e-05	CbGpPWpGaD
Vandetanib—FYN—Developmental Biology—IL6—polycystic ovary syndrome	2.88e-06	1.87e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—SERPINE1—polycystic ovary syndrome	2.88e-06	1.86e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—INS—polycystic ovary syndrome	2.87e-06	1.86e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—BCL2—polycystic ovary syndrome	2.86e-06	1.86e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—CYP1A1—polycystic ovary syndrome	2.85e-06	1.85e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.84e-06	1.84e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—AKT2—polycystic ovary syndrome	2.83e-06	1.84e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—GNAS—polycystic ovary syndrome	2.83e-06	1.83e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—IRS1—polycystic ovary syndrome	2.83e-06	1.83e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—SRD5A1—polycystic ovary syndrome	2.81e-06	1.82e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—AKR1C3—polycystic ovary syndrome	2.8e-06	1.82e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—AKT2—polycystic ovary syndrome	2.78e-06	1.8e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—NGFR—polycystic ovary syndrome	2.77e-06	1.79e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—IRS2—polycystic ovary syndrome	2.76e-06	1.79e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—CYP17A1—polycystic ovary syndrome	2.76e-06	1.79e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—PRL—polycystic ovary syndrome	2.75e-06	1.78e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.74e-06	1.78e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—AKT2—polycystic ovary syndrome	2.73e-06	1.77e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—GNAS—polycystic ovary syndrome	2.73e-06	1.77e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—IRS1—polycystic ovary syndrome	2.72e-06	1.76e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—IRS2—polycystic ovary syndrome	2.72e-06	1.76e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—INS—polycystic ovary syndrome	2.71e-06	1.75e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—NCOR1—polycystic ovary syndrome	2.7e-06	1.75e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—STAR—polycystic ovary syndrome	2.68e-06	1.74e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—IRS2—polycystic ovary syndrome	2.67e-06	1.73e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—LEP—polycystic ovary syndrome	2.66e-06	1.73e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—MTHFR—polycystic ovary syndrome	2.66e-06	1.72e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—NRG1—polycystic ovary syndrome	2.65e-06	1.71e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Innate Immune System—IL6—polycystic ovary syndrome	2.64e-06	1.71e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—SERPINE1—polycystic ovary syndrome	2.64e-06	1.71e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—IRS2—polycystic ovary syndrome	2.62e-06	1.7e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—AKT2—polycystic ovary syndrome	2.62e-06	1.69e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—IRS1—polycystic ovary syndrome	2.61e-06	1.69e-05	CbGpPWpGaD
Vandetanib—RIPK2—Immune System—IL6—polycystic ovary syndrome	2.61e-06	1.69e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—LEP—polycystic ovary syndrome	2.61e-06	1.69e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—INS—polycystic ovary syndrome	2.61e-06	1.69e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—ADRB2—polycystic ovary syndrome	2.6e-06	1.69e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—NCOR1—polycystic ovary syndrome	2.6e-06	1.68e-05	CbGpPWpGaD
Vandetanib—LYN—Innate Immune System—IL6—polycystic ovary syndrome	2.59e-06	1.67e-05	CbGpPWpGaD
Vandetanib—ABL1—Innate Immune System—IL6—polycystic ovary syndrome	2.57e-06	1.67e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—LEP—polycystic ovary syndrome	2.57e-06	1.66e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—NRG1—polycystic ovary syndrome	2.55e-06	1.65e-05	CbGpPWpGaD
Vandetanib—FYN—Innate Immune System—IL6—polycystic ovary syndrome	2.55e-06	1.65e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—AKT2—polycystic ovary syndrome	2.52e-06	1.63e-05	CbGpPWpGaD
Vandetanib—BLK—Immune System—IL6—polycystic ovary syndrome	2.51e-06	1.63e-05	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—IL6—polycystic ovary syndrome	2.51e-06	1.63e-05	CbGpPWpGaD
Vandetanib—FGR—Immune System—IL6—polycystic ovary syndrome	2.5e-06	1.62e-05	CbGpPWpGaD
Vandetanib—EGFR—Developmental Biology—IL6—polycystic ovary syndrome	2.49e-06	1.61e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—SERPINE1—polycystic ovary syndrome	2.49e-06	1.61e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—BCL2—polycystic ovary syndrome	2.47e-06	1.6e-05	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—PPARG—polycystic ovary syndrome	2.45e-06	1.59e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.44e-06	1.58e-05	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—POMC—polycystic ovary syndrome	2.42e-06	1.57e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—AKT2—polycystic ovary syndrome	2.42e-06	1.57e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—GNAS—polycystic ovary syndrome	2.41e-06	1.56e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—IRS1—polycystic ovary syndrome	2.41e-06	1.56e-05	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—INS—polycystic ovary syndrome	2.4e-06	1.56e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—SERPINE1—polycystic ovary syndrome	2.4e-06	1.55e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—TH—polycystic ovary syndrome	2.39e-06	1.55e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—HMMR—polycystic ovary syndrome	2.39e-06	1.55e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—BCL2—polycystic ovary syndrome	2.39e-06	1.55e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—IRS1—polycystic ovary syndrome	2.38e-06	1.54e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—IRS1—polycystic ovary syndrome	2.33e-06	1.51e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—SLC2A4—polycystic ovary syndrome	2.32e-06	1.51e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—INS—polycystic ovary syndrome	2.31e-06	1.5e-05	CbGpPWpGaD
Vandetanib—ERBB3—Immune System—IL6—polycystic ovary syndrome	2.3e-06	1.49e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—NCOR1—polycystic ovary syndrome	2.3e-06	1.49e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—IRS1—polycystic ovary syndrome	2.29e-06	1.48e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—POMC—polycystic ovary syndrome	2.29e-06	1.48e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—HSD3B1—polycystic ovary syndrome	2.28e-06	1.48e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—INS—polycystic ovary syndrome	2.28e-06	1.47e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—IRS2—polycystic ovary syndrome	2.27e-06	1.47e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—NRG1—polycystic ovary syndrome	2.26e-06	1.46e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—POMC—polycystic ovary syndrome	2.24e-06	1.45e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—AKT2—polycystic ovary syndrome	2.23e-06	1.45e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.23e-06	1.45e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—INS—polycystic ovary syndrome	2.23e-06	1.44e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—LEP—polycystic ovary syndrome	2.22e-06	1.44e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—POMC—polycystic ovary syndrome	2.21e-06	1.43e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—IGF1—polycystic ovary syndrome	2.2e-06	1.43e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—AKT2—polycystic ovary syndrome	2.2e-06	1.42e-05	CbGpPWpGaD
Vandetanib—EGFR—Innate Immune System—IL6—polycystic ovary syndrome	2.2e-06	1.42e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—INS—polycystic ovary syndrome	2.19e-06	1.42e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—CYP19A1—polycystic ovary syndrome	2.18e-06	1.42e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—IRS2—polycystic ovary syndrome	2.18e-06	1.42e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.17e-06	1.41e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—PPARG—polycystic ovary syndrome	2.16e-06	1.4e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—IGF1—polycystic ovary syndrome	2.16e-06	1.4e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—AKT2—polycystic ovary syndrome	2.15e-06	1.4e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—VEGFA—polycystic ovary syndrome	2.15e-06	1.39e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—LEP—polycystic ovary syndrome	2.14e-06	1.38e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—POMC—polycystic ovary syndrome	2.13e-06	1.38e-05	CbGpPWpGaD
Vandetanib—SRC—Developmental Biology—IL6—polycystic ovary syndrome	2.12e-06	1.38e-05	CbGpPWpGaD
Vandetanib—ERBB3—Disease—IL6—polycystic ovary syndrome	2.12e-06	1.38e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—IGF1—polycystic ovary syndrome	2.12e-06	1.37e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—SERPINE1—polycystic ovary syndrome	2.12e-06	1.37e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—AKT2—polycystic ovary syndrome	2.12e-06	1.37e-05	CbGpPWpGaD
Vandetanib—LCK—Innate Immune System—IL6—polycystic ovary syndrome	2.12e-06	1.37e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—INS—polycystic ovary syndrome	2.12e-06	1.37e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—BCL2—polycystic ovary syndrome	2.11e-06	1.37e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.09e-06	1.35e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—LHB—polycystic ovary syndrome	2.08e-06	1.35e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.05e-06	1.33e-05	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—VEGFA—polycystic ovary syndrome	2.03e-06	1.32e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—HSD3B2—polycystic ovary syndrome	2.03e-06	1.32e-05	CbGpPWpGaD
Vandetanib—YES1—Immune System—IL6—polycystic ovary syndrome	2.02e-06	1.31e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—SERPINE1—polycystic ovary syndrome	2.02e-06	1.31e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—IRS1—polycystic ovary syndrome	1.98e-06	1.28e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—AKR1C1—polycystic ovary syndrome	1.97e-06	1.27e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—GNAS—polycystic ovary syndrome	1.95e-06	1.26e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—IRS2—polycystic ovary syndrome	1.93e-06	1.25e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—IRS1—polycystic ovary syndrome	1.91e-06	1.24e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—POMC—polycystic ovary syndrome	1.91e-06	1.23e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—INS—polycystic ovary syndrome	1.9e-06	1.23e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—LEP—polycystic ovary syndrome	1.89e-06	1.23e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.89e-06	1.22e-05	CbGpPWpGaD
Vandetanib—SRC—Innate Immune System—IL6—polycystic ovary syndrome	1.88e-06	1.22e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—NCOR1—polycystic ovary syndrome	1.86e-06	1.2e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—POMC—polycystic ovary syndrome	1.84e-06	1.19e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—IGF1—polycystic ovary syndrome	1.83e-06	1.19e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—AKT2—polycystic ovary syndrome	1.83e-06	1.19e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—INS—polycystic ovary syndrome	1.83e-06	1.18e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—SULT2A1—polycystic ovary syndrome	1.81e-06	1.17e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—IGF1—polycystic ovary syndrome	1.77e-06	1.14e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—AKT2—polycystic ovary syndrome	1.77e-06	1.14e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—CYP1A1—polycystic ovary syndrome	1.76e-06	1.14e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—RRM2—polycystic ovary syndrome	1.75e-06	1.14e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.74e-06	1.13e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—YAP1—polycystic ovary syndrome	1.69e-06	1.09e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—IRS1—polycystic ovary syndrome	1.69e-06	1.09e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—IL6—polycystic ovary syndrome	1.69e-06	1.09e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.68e-06	1.09e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—MTHFR—polycystic ovary syndrome	1.64e-06	1.06e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—POMC—polycystic ovary syndrome	1.63e-06	1.05e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—NAMPT—polycystic ovary syndrome	1.62e-06	1.05e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—INS—polycystic ovary syndrome	1.62e-06	1.05e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CYP11A1—polycystic ovary syndrome	1.6e-06	1.04e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—IGF1—polycystic ovary syndrome	1.56e-06	1.01e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—AKT2—polycystic ovary syndrome	1.56e-06	1.01e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—IL6—polycystic ovary syndrome	1.54e-06	1e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—IL6—polycystic ovary syndrome	1.54e-06	9.96e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—AKR1C3—polycystic ovary syndrome	1.51e-06	9.81e-06	CbGpPWpGaD
Vandetanib—LYN—Immune System—IL6—polycystic ovary syndrome	1.51e-06	9.76e-06	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—IL6—polycystic ovary syndrome	1.5e-06	9.74e-06	CbGpPWpGaD
Vandetanib—ABL1—Immune System—IL6—polycystic ovary syndrome	1.5e-06	9.71e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CYP17A1—polycystic ovary syndrome	1.49e-06	9.65e-06	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—IL6—polycystic ovary syndrome	1.49e-06	9.64e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—SERPINE1—polycystic ovary syndrome	1.49e-06	9.62e-06	CbGpPWpGaD
Vandetanib—FYN—Immune System—IL6—polycystic ovary syndrome	1.48e-06	9.6e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.44e-06	9.31e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—IL6—polycystic ovary syndrome	1.42e-06	9.2e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.41e-06	9.12e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—IL6—polycystic ovary syndrome	1.4e-06	9.08e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.39e-06	8.98e-06	CbGpPWpGaD
Vandetanib—FYN—Disease—IL6—polycystic ovary syndrome	1.37e-06	8.87e-06	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—IL6—polycystic ovary syndrome	1.35e-06	8.76e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PPARG—polycystic ovary syndrome	1.33e-06	8.62e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—POMC—polycystic ovary syndrome	1.31e-06	8.51e-06	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—IL6—polycystic ovary syndrome	1.31e-06	8.46e-06	CbGpPWpGaD
Vandetanib—ALB—Metabolism—INS—polycystic ovary syndrome	1.31e-06	8.46e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—TH—polycystic ovary syndrome	1.29e-06	8.35e-06	CbGpPWpGaD
Vandetanib—EGFR—Immune System—IL6—polycystic ovary syndrome	1.28e-06	8.3e-06	CbGpPWpGaD
Vandetanib—ABCC1—Disease—IL6—polycystic ovary syndrome	1.25e-06	8.13e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—SLC2A4—polycystic ovary syndrome	1.25e-06	8.13e-06	CbGpPWpGaD
Vandetanib—LCK—Immune System—IL6—polycystic ovary syndrome	1.23e-06	8e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.2e-06	7.76e-06	CbGpPWpGaD
Vandetanib—EGFR—Disease—IL6—polycystic ovary syndrome	1.18e-06	7.66e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CYP19A1—polycystic ovary syndrome	1.18e-06	7.64e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.15e-06	7.47e-06	CbGpPWpGaD
Vandetanib—LCK—Disease—IL6—polycystic ovary syndrome	1.14e-06	7.38e-06	CbGpPWpGaD
Vandetanib—SRC—Immune System—IL6—polycystic ovary syndrome	1.09e-06	7.08e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—GNAS—polycystic ovary syndrome	1.05e-06	6.82e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—VEGFA—polycystic ovary syndrome	1.02e-06	6.62e-06	CbGpPWpGaD
Vandetanib—SRC—Disease—IL6—polycystic ovary syndrome	1.01e-06	6.54e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—NCOR1—polycystic ovary syndrome	1e-06	6.5e-06	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—IL6—polycystic ovary syndrome	9.94e-07	6.44e-06	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—IL6—polycystic ovary syndrome	9.74e-07	6.31e-06	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—IL6—polycystic ovary syndrome	9.59e-07	6.21e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—CYP1A1—polycystic ovary syndrome	9.51e-07	6.16e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—MTHFR—polycystic ovary syndrome	8.86e-07	5.74e-06	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—IL6—polycystic ovary syndrome	8.28e-07	5.36e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—IL6—polycystic ovary syndrome	7.98e-07	5.17e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PPARG—polycystic ovary syndrome	7.19e-07	4.66e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—POMC—polycystic ovary syndrome	7.09e-07	4.59e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—IL6—polycystic ovary syndrome	7.07e-07	4.58e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—INS—polycystic ovary syndrome	7.05e-07	4.57e-06	CbGpPWpGaD
